IMMUNIC, INC.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
IMUX$8.04+1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(In thousands, except share amounts)
| Six Months Ended June 30, 2025 | ||||||
|---|---|---|---|---|---|---|
| Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensiveIncome · AccumulatedDeficit · TotalStockholders’Equity (Deficit) | ||||||
| Shares · Amount | ||||||
| Balance at January 1, 2025 | 90,150,869 | $8 | $525,611 | $4,209 | $(511,399) | $18,429 |
| Net loss | — | — | — | — | (25,473) | (25,473) |
| Stock-based compensation | — | — | 2,042 | — | — | 2,042 |
| Foreign exchange translation adjustment | — | — | — | (285) | — | (285) |
| Balance at March 31, 2025 | 90,150,869 | $8 | $527,653 | $3,924 | $(536,872) | $(5,287) |
| Net loss | — | — | — | — | (26,820) | (26,820) |
| Stock-based compensation | — | — | 1,899 | — | — | 1,899 |
| Foreign exchange translation adjustment | — | — | — | (1,399) | — | (1,399) |
| Issuance of pre-funded warrants - May 2025 Offering, net of issuance costs of $4,332 | — | — | 60,661 | — | — | 60,661 |
| Issuance of common stock - April 2025 Offering, net of issuance costs of $367 | 5,666,667 | 1 | 4,733 | — | — | 4,734 |
| Exercise of pre-funded warrants from January 2024 Financing | 2,613,057 | — | — | — | — | — |
| Shares issued in connection with the Company's employee stock purchase plan | 219,997 | — | 123 | — | — | 123 |
| Balance at June 30, 2025 | 98,650,590 | $9 | $595,069 | $2,525 | $(563,692) | $33,911 |
| Six Months Ended June 30, 2024 | ||||||
|---|---|---|---|---|---|---|
| Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensiveIncome · AccumulatedDeficit · TotalStockholders’Equity (Deficit) | ||||||
| Shares · Amount | ||||||
| Balance at January 1, 2024 | 45,177,730 | $4 | $436,060 | $3,759 | $(410,892) | $28,931 |
| Net loss | — | — | — | — | (29,584) | (29,584) |
| Stock-based compensation | — | — | 2,750 | — | — | 2,750 |
| Foreign exchange translation adjustment | — | — | — | 528 | — | 528 |
| Issuance of common stock and pre-funded warrants - January 2024 Financing, net of issuance costs of $4,037 | 44,751,286 | 4 | 52,360 | — | — | 52,364 |
| Conversion of tranche rights liability to equity | — | — | 28,396 | — | — | 28,396 |
| Issuance of common stock - At The Market Sales Agreement net of issuance costs of $6 | 150,000 | — | 191 | — | — | 191 |
| Balance at March 31, 2024 | 90,079,016 | $8 | $519,757 | $4,287 | $(440,476) | $83,576 |
| Net loss | — | — | — | — | (21,380) | (21,380) |
| Stock-based compensation | — | — | 1,882 | — | — | 1,882 |
| Foreign exchange translation adjustment | — | — | — | (505) | — | (505) |
| Balance at June 30, 2024 | 90,079,016 | $8 | $521,639 | $3,782 | $(461,856) | $63,573 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.